Compare VBF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VBF | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.8M | 266.4M |
| IPO Year | 1995 | 2010 |
| Metric | VBF | FENC |
|---|---|---|
| Price | $15.08 | $7.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 76.5K | ★ 123.4K |
| Earning Date | 01-01-0001 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 96.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $47,538,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.69 |
| 52 Week Low | $14.33 | $4.68 |
| 52 Week High | $15.98 | $9.92 |
| Indicator | VBF | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 44.24 |
| Support Level | N/A | $7.44 |
| Resistance Level | $15.62 | $8.27 |
| Average True Range (ATR) | 0.11 | 0.44 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 11.11 | 25.36 |
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.